Fibrotic Tumors in a Clinical Array of PDAC can be Selectively Identified and Monitored by Collagen Hybridizing Peptides

Pancreatic Ductal Adenocarcinoma (PDAC) poses a wide range of diagnosis and treatment challenges. First, PDAC is difficult to diagnose; by the time patients present symptoms, they most likely have an advanced form of the disease, and the diagnosis is typically fatal. Furthermore, PDAC symptoms are not specific, meaning the condition is often misdiagnosed.

Our R-CHP is Conjugated with Cy3. Contact us for customized conjugates.

Contact Us
Understanding Pancreatic Ductal Adenocarcinoma

Understanding PDAC

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive type of pancreatic neoplasm, stemming from the lack of an early diagnosis and limited response to treatments. PDAC is developed in the exocrine compartment, and has extremely high heterogeneity. Symptoms include tumors, weight loss, abdominal pain, and jaundice. Despite scientific progress, PDAC has an average 5-year survival rate of less than 10%, and is expected to become one of the top leading causes of cancer-related mortality.
Current Treatment Challenges
The current standard of care for PDAC includes surgery, chemotherapy, radiation, and palliative therapy. Unfortunately, the lack of an early diagnosis allows tumors to grow to a large size, making surgical removal difficult. Not only that, but tumors can develop resistance to chemotherapy and suppress immune cells, making therapy even more troublesome.
Why CHPs?
CHP fluorescent staining can efficiently and selectively identify the degenerated collagen matrix at each stage in a clinical tissue array of PDAC. Such identification serves as a major advancement in the analysis of PDAC development, working to help the hundreds of thousands suffering from this disease.